

PRIOR AUTHORIZATION CRITERIA

DRUG CLASS	ANABOLIC STEROIDS
-------------------	--------------------------

BRAND NAME (generic)

ANADROL-50 (oxymetholone)
--

Status: CVS Caremark Criteria

Type: Initial Prior Authorization

Policy

FDA-APPROVED INDICATIONS

Anadrol-50 is indicated in the treatment of anemias caused by deficient red cell production. Acquired aplastic anemia, congenital aplastic anemia, myelofibrosis and the hypoplastic anemias due to the administration of myelotoxic drugs often respond. Anadrol tablets should not replace other supportive measures such as transfusion, correction of iron, folic acid, vitamin B₁₂ or pyridoxine deficiency, antibacterial therapy and the appropriate use of corticosteroids.

Compendial Uses

Fanconi's Anemia^{2, 3, 4}

Cachexia associated with AIDS³

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for any of the following: A) Anemia due to deficient red-cell production, (e.g. acquired aplastic anemia, congenital aplastic anemia, myelofibrosis, or the hypoplastic anemias due to the administration of myelotoxic drugs), B) Fanconi's anemia, C) Cachexia associated with AIDS (HIV-wasting)

REFERENCES

1. Anadrol-50 [package insert]. Marietta, GA: Alaven Pharmaceuticals LLC; December 2006.
2. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed February 2018.
3. Micromedex Solutions [database online]. Greenwood Village, CO: Truven Health Analytics Inc. Updated periodically. www.micromedexsolutions.com [available with subscription]. Accessed February 2018.
4. Fanconi Anemia Research Fund, Inc. Fanconi Anemia: Guidelines for Diagnosis and Management Fourth Edition, 2014. http://fanconi.org/images/uploads/other/Guidelines_4th_Edition.pdf. Accessed February 2018.
5. Food and Drug Administration. Testosterone and other anabolic androgenic steroids (AAS): FDA statement – risks associated with abuse and dependence. Silver Spring, MD; 2016 Oct 25. Available at: <https://wayback.archive-it.org/7993/20170111133941/http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm526151.htm>. Accessed February 2018.